证券代码：300049 证券简称：福瑞股份 公告编号：2024-016 内蒙古福瑞医疗科技股份有限公司 关于使用闲置自有资金进行委托理财的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第 八届董事会第七次会议，审议通过了《关于使用闲置自有资金进行委托理财的议案》，同 意公司及子公司（以下统称为"公司"）在不影响资金安全及风险可控的前提下，使用合 计不超过人民币 30,000 万元的自有资金进行委托理财。上述资金额度经公司董事会审议通 过之日起 12 个月内有效，上述额度在授权期限内，可循环滚动使用。本事项在董事会审批 权限范围内，无需提交公司股东大会审议。现将相关情况公告如下： 一、委托理财基本情况 1、投资目的 公司在不影响日常经营资金使用和确保资金安全的前提下，为提高公司闲置资金的使 用效率，合理利用公司闲置自有资金，进一步提高整体收益，拟使用闲置自有资金进行委 托理财。 2、投资额度及期限 公司拟使用不超过人民币 30,000 万元闲置自有资金进行委托理财，使 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2024-018 内蒙古福瑞医疗科技股份有限公司 关于收购杭州睿颖健康产业股权投资基金合伙企业（有限合伙） 部分基金份额暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、交易概述 1、内蒙古福瑞医疗科技股份有限公司（以下简称"公司"、"福瑞股份"）将收购 福州新海投资合伙企业（有限合伙）（以下简称"新海投资"）持有的杭州睿颖健康产 业股权投资基金合伙企业（有限合伙）（以下简称"标的基金"、"睿颖基金"）386.2319 万元的基金份额。同时，公司将收购闫瑞峰持有的标的基金 3,713.7681 万元的基金份额。 本次交易完成后，公司将成为持有睿颖基金人民币 4,100 万元实缴出资额对应合伙份额的 有限合伙人。收购完成后，公司直接持有标的基金的比例将由 30.20%增至 50.50%，标的 基金不纳入公司合并报表范围。本次收购基金份额的资金来源为公司自有资金。 2、截至 2023 年 5 月 29 日，中国国投高新产业投资有限公司为公司持股 5%以上股 东，其持有福州新海投资合伙企业（有 ...

内蒙古福瑞医疗科技股份有限公司 独立董事述职报告 内蒙古福瑞医疗科技股份有限公司 独立董事 2023 年度述职报告 | 独立董 | 应参加董 | 现场出席董 | 以通讯方式参 | 委托出席董 | 缺席董事 | 是否连续两次未亲 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | --- | | 事姓名 | 事会次数 | 事会次数 | 加董事会次数 | 事会次数 | 会次数 | 自参加董事会会议 | 大会次数 | | 郭朋 | 7 | 1 | 6 | 0 | 0 | 否 | 0 | 具体出席会议情况如下： （郭朋） 作为内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）董事会独立董事，2023 年本人严格按照《中华人民共和国公司法》、《深圳证券交易所创业板股票上市规则》和 《公司章程》等相关法律法规及规定的要求，诚实、勤勉、独立地履行职责，积极出席相 关会议，认真审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董 事的作用，切实维护了公司整体利益和全体股东特别是中小股东的合法权益。现将2023年 度履行独立董事职责的情况报告如下： 一、基本情 ...

内蒙古福瑞医疗科技股份有限公司 独立董事工作细则 内蒙古福瑞医疗科技股份有限公司 独立董事工作细则 第一章 总则 第一条 为进一步完善内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）的 公司治理结构，促进公司规范运作，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》等法律、法规和规范性文件以及《内蒙古福瑞医 疗科技股份有限公司章程》（以下简称《公司章程》）等有关规定，制定本工作细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及主要股东、 实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客观判断关 系的董事。 独立董事应当独立履行职责，不受上市公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有诚信与勤勉义务，并应当按照法律、行政 法规、证监会规定、证券交易所业务规则和公司章程的规定，认真履行职责，在董事 会中发挥参与决策、监督制衡、专业咨询的作用，维护公司整体利益，保护中小股东 的合法权益。 第四条 公司独立董事占董事会成员的比例 ...

内蒙古福瑞医疗科技股份有限公司 内部控制审计报告 大华内字[2024]0011000153 号 内部控制审计报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 内蒙古福瑞医疗科技股份有限公司 内 部 控 制 审 计 报 告 大华内字[2024]0011000153 号 内蒙古福瑞医疗科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了内蒙古福瑞医疗科技股份有限公司（以下简称福 瑞股份）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《 ...

Financial Performance - Cash and cash equivalents increased to ¥509,588,759.88, representing 19.25% of total assets, up from 18.99% at the beginning of the year[1] - The company reported a net profit of ¥175,984,463.56 from its investment in Echosens S.A.S., which represents 19.63% of the company's net assets[1] - The company's total operating revenue for the medical sector reached ¥1,153,733,886.38, representing a year-on-year increase of 14.37%[50] - Net profit attributable to shareholders for 2023 was ¥101,563,741.25, a 3.75% increase from the adjusted net profit of ¥97,889,810.41 in 2022[179] - The net cash flow from operating activities for 2023 was ¥304,889,063.36, marking a significant increase of 60.92% compared to ¥189,461,778.48 in 2022[179] Investments and Assets - Long-term equity investments rose to ¥110,932,357.84, accounting for 4.19% of total assets, an increase of 1.78% compared to the beginning of the year[1] - The company invested ¥189,228,473.46 during the reporting period, a significant increase of 108.46% compared to ¥90,775,052.56 in the same period last year[9] - The total amount of restricted assets at the end of the reporting period was ¥64,581,317.18, including fixed assets, intangible assets, and investment properties[6] - The company has a total of ¥44,902,398.16 in lease liabilities, which is 1.70% of total assets[1] - The company’s financial assets measured at fair value increased to ¥94,111,695.27 at the end of the reporting period[5] Sales and Revenue - Revenue from medical devices and technology was ¥831,607,278.76, with a year-on-year growth of 35.40%[50] - The sales volume of diagnostic instruments rose by 25.36% to 1,142 units in 2023, up from 911 units in 2022[32] - The total sales amount from the top five customers was 132,827,426.85 yuan, accounting for 11.51% of the annual total sales[38] - Domestic revenue was ¥395,722,877.40, showing a decline of 11.98% year-on-year, while overseas revenue was ¥758,011,008.98, with a growth of 35.56%[50] Research and Development - Research and development expenses increased by 16.45% to 82,468,003.10 yuan in 2023 from 70,815,457.58 yuan in 2022[42] - The company plans to enhance the Fibroscan product line to expand its application in the medical field, which is expected to improve competitiveness[42] - The company is actively involved in the development of new medical technologies and products[118] - Research and development investments have increased by 25%, focusing on advanced medical technologies[112] Strategic Plans and Market Expansion - The company plans to implement a management-based medical strategy focusing on liver cancer screening and prevention, aiming to reduce liver cancer incidence and related mortality rates[25] - In 2024, the company aims to enhance the market share of FibroScanBOX and expand its management-based medical strategy across domestic markets[28] - The company will strengthen overseas investments, particularly in the US and European markets, to optimize resource allocation and expand its liver disease diagnostic equipment business[29] - The company is committed to expanding its market presence, although specific strategies or targets have not been detailed in the report[92] Governance and Management - The company has established an independent financial department with a complete financial management system, ensuring no interference from major shareholders[84] - The company maintains a fully independent operational structure, with no shared offices or mixed operations with controlling shareholders[85] - The company has a complete asset ownership structure, with no assets occupied by major shareholders or related parties[82] - The company has implemented a governance structure that aligns with the requirements of the China Securities Regulatory Commission[73] Employee and Compensation - The total remuneration paid to directors, supervisors, and senior management in 2023 amounted to 4.7475 million yuan[119] - The company has a performance bonus system where bonuses typically range from 15% to 20% of monthly salaries based on performance evaluations[146] - The company has a training program focused on management and marketing personnel to adapt to changes in the healthcare industry[149] - The employee stock ownership plan (ESOP) includes 76 participants, with a total of 6,718,233 shares held, representing 2.55% of the company's total equity[193] Risks and Challenges - The company is facing risks related to the fluctuation of raw material prices, particularly for winter worm grass, which significantly impacts production costs[54] - The medical services segment's contribution to revenue remains low, indicating potential risks in its development trajectory[57] - The company aims to improve operational efficiency, targeting a 10% reduction in costs through process optimization[112] Transparency and Reporting - The company has committed to transparent information disclosure, ensuring all investors have equal access to company information[77] - The annual report is disclosed on the Shenzhen Stock Exchange and various financial news platforms, ensuring transparency[176] - The company emphasizes that all board members attended the meeting to review the annual report, ensuring the accuracy and completeness of the financial statements[158]

Financial Performance - The company's revenue for Q1 2024 reached ¥322,803,586.32, representing a 33.35% increase compared to ¥242,063,684.65 in the same period last year [19] - Net profit attributable to shareholders was ¥42,719,144.08, a significant increase of 228.57% from ¥13,001,623.68 in the previous year [19] - The net profit after deducting non-recurring gains and losses was ¥41,291,171.98, up 126.24% from ¥18,251,415.69 year-on-year [19] - Basic earnings per share rose to ¥0.1624, reflecting a 228.74% increase compared to ¥0.0494 in the same period last year [19] - The company achieved total operating revenue of 323 million RMB, a year-on-year increase of 33.35% [26] - Net profit attributable to shareholders reached 42.72 million RMB, up 228.57% compared to the same period last year [26] - The net profit excluding non-recurring gains and losses was 41.29 million RMB, reflecting a growth of 126.24% year-on-year [26] - The total comprehensive income for the period was CNY 48,359,540.62, compared to CNY 41,774,567.26 in the previous period, representing an increase of approximately 13.8% [44] - Basic and diluted earnings per share increased to CNY 0.1624 from CNY 0.0494, marking a significant growth of 228.4% [44] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,683,857,409.32, a 1.37% increase from ¥2,647,472,861.45 at the end of the previous year [19] - The company's total assets increased to ¥2,683,857,409.32 from ¥2,647,472,861.45, marking a growth of 1.4% [41] - Current liabilities totaled ¥301,255,455.54, slightly up from ¥298,367,511.93, indicating a marginal increase of 0.6% [41] - Non-current liabilities rose to ¥532,924,699.40 from ¥501,725,944.13, reflecting a 6.2% increase [41] - The total equity attributable to shareholders increased to ¥1,566,671,495.95 from ¥1,547,323,178.35, a growth of 1.3% [41] Cash Flow - Cash flow from operating activities decreased by 45.47% to ¥38,481,610.14 from ¥70,573,746.91 in the previous year [19] - The company's cash flow from operating activities showed significant improvement, contributing to the overall financial health [36] - Cash inflows from operating activities totaled CNY 326,178,886.99, slightly up from CNY 325,225,260.79, indicating stable operational performance [48] - Net cash flow from operating activities decreased to CNY 38,481,610.14 from CNY 70,573,746.91, reflecting a decline of approximately 45.4% [49] - Cash and cash equivalents at the end of the period were CNY 492,907,321.64, down from CNY 535,049,843.40, a decrease of approximately 7.9% [49] - The company received CNY 13,096,924.05 in cash from financing activities, a significant increase from CNY 422,532.12 in the previous period [49] - The net cash flow from financing activities improved to CNY 8,562,547.47 from CNY -2,714,178.14, indicating a positive shift in financing operations [49] Operational Highlights - The growth in performance is primarily attributed to the continuous expansion of the company's medical device business [26] - The company has adopted a management-oriented medical strategy focusing on "new pathways for high-risk liver cancer screening + new strategies for secondary prevention + value-based payment for traditional Chinese medicine" as its core direction [26] - The company is transitioning towards an academic project-oriented drug marketing model, significantly enhancing its performance in drug sales and managed medical services [26] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth [34] Taxation and Expenses - Tax payable increased by 43% to ¥54,300,887.42, attributed to higher revenue leading to increased value-added tax [22] - The company experienced a 120% increase in taxes and surcharges, amounting to ¥2,101,548.89, due to increased sales of pharmaceuticals and medical devices [22] - Operating costs for the first quarter were ¥234,675,665.98, up from ¥185,573,350.49, reflecting a 26.5% increase [41] - The company reported a decrease in accounts payable from ¥80,093,496.70 to ¥71,318,092.45, a reduction of 10.5% [41]

内蒙古福瑞医疗科技股份有限公司 董事会审计委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及内蒙古福瑞医疗科技股份有限公司（以 下简称"公司"）《公司章程》《董事会审计委员会工作细则》等规定和要求，董事会 审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会计 师事务所 2023 年度履职情况评估及履行监督职责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 (一)会计师事务所基本情况 机构名称：大华会计师事务所（特殊普通合伙） 成立日期：2012 年 2 月 9 日成立（由大华会计师事务所有限公司转制为特殊普通合 伙企业） 组织形式：特殊普通合伙 注册地址：北京市海淀区西四环中路 16 号院 7 号楼 1101 首席合伙人：梁春 截至 2023 年 12 月 31 日合伙人数量：270 人 截至 2023 年 12 月 31 日注册会计师人数：1471 人 ...

2023 年度内部控制评价报告 根据《上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《企业 内部控制基本规范》及其配套指引的规定和要求，内蒙古福瑞医疗科技股份有限 公司（以下简称"公司"）对 2023 年度内部控制的有效性进行了评价。 一、内部控制评价的依据 根据中华人民共和国财政部等五部委联合发布的《企业内部控制基本规范》 及《企业内部控制评价指引》的要求，结合公司内部控制制度和评价办法，在内 部控制日常监督和专项监督的基础上，对公司截至 2023 年 12 月 31 日内部控制 的设计与运行的有效性进行评价。 二、建立内部控制制度的目标和遵循的原则 （一）内部控制目标 公司建立内部控制制度的目标是合理保证企业经营管理合法合规、资产安全、 财务报告及相关信息真实完整，提高经营效率和效果，促进公司实现发展战略。 1. 合理保证公司各项业务活动合法合规，确保公司管理的各个方面符合国家 有关法律、法规。 2. 建立和完善符合上市公司要求的公司治理结构及内部组织结构，形成科学 的决策机制、执行机制和考核机制，保证公司经营管理目标的全面实现。 3. 建立健全行之有效的风险控制系统，强化风险管理，保证公司 ...

内蒙古福瑞医疗科技股份有限公司 关于董事会、监事会部分成员变更、调整董事会专门委员会 成员暨聘任高级管理人员及证券事务代表的公告 本公司及董事会、监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 第八届董事会第七次会议、第八届监事会第七次会议、职工代表大会分别审议通过了《关 于调整公司第八届董事会专门委员会成员的议案》《关于聘任高级管理人员的议案》《关 于聘任证券事务代表的议案》及选举第八届监事会职工代表监事和监事会主席等相关议 案，现将相关情况公告如下： 一、关于董事、监事、高级管理人员、证券事务代表辞职的情况 公司董事会、监事会于近日分别收到公司董事李哲先生、独立董事耿方圆先生、副 总经理杨勇先生、证券事务代表万慧女士及监事会主席王立群女士、监事王丹丹女士、 田朗女士提交的书面辞职申请。李哲先生因工作变动原因，申请辞去公司董事及专门委 员会相关职务，辞职后不再担任公司任何职务；耿方圆先生因工作变动原因，申请辞去 公司独立董事及专门委员会相关职务，辞职后不再担任公司任何职务；杨勇 ...